Biotinylated Recombinant Human PD-L1 (C-Fc-Avi) (CU02)
产品说明(Description) Biotinylated Recombinant Human Programmed Cell Death 1 Ligand 1 is produced by our Mammalianexpression system and the target gene encoding Phe19-Thr239 is expressed with a Fc, Avi tag at the C-terminus. Accession #: Q9NZQ7 Known as: Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1
制剂(Formulation) Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4.
质量控制(Quality Control)
Purity:
Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin:
Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test.
Biotin:Protein Ratio The biotin to protein ratio is 0.5-1 as determined by the HABA assay. Bioactivity:
Immobilized Anti-Human PDL1 mAb-FC at 2μg/ml (100 μl/well) can bind Human PD-L1-Avi(Cat#CU02).The ED50 of Human PD-L1-Avi(Cat#CU02) is 0.25 ug/ml.
Immobilized Recombinant Human PD-1-His(Cat#CX91) at 5μg/ml (100 μl/well)can bind Human PD-L1-Fc-Avi(Cat#CU02). The ED50 of Human PD-L1-Fc-Avi(Cat#CU02) is 0.185 ug/ml.
复溶(Reconstitution) Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
保存(Storage) Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months.
背景(Background) CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.